Myofascial Induction Therapy Improves the Sequelae of Medical Treatment in Head and Neck Cancer Survivors: A Single-Blind, Placebo-Controlled, Randomized Cross-Over Study

Head and neck cancer (HNC) is the sixth most common cancer worldwide. Yet, less than 60% of HNC survivors receive adequate therapy for treatment-related sequelae. The objective of this study was to determine the efficacy of myofascial induction therapy (MIT) in improving cervical and shoulder pain and range of motion, maximal mouth opening, and cervical muscle function in HNC survivors. This crossover, blinded, placebo-controlled study involved 22 HNC survivors (average age 56.55 & PLUSMN; 12.71) of which 13 were males (59.1%) who received, in a crossover fashion, both a single 30-min session of MIT in the form of manual unwinding and simulated pulsed shortwave therapy (placebo), with a 4-week washout interval between the two. Cervical and shoulder pain (visual analogue scale) and range of motion (cervical range of motion device and goniometer), maximum mouth opening (digital caliper), and cervical muscle function (deep cervical flexor endurance test) were measured before and after the treatment and placebo sessions. A single session of MIT improved cervical and affected side shoulder pain, cervical range of motion, maximum mouth opening, and cervical muscle function. The associated effect sizes ranged from moderate to large. The present study suggests that MIT, in the form of manual unwinding, improves cervical (-3.91 & PLUSMN; 2.77) and affected-side shoulder (-3.64 & PLUSMN; 3.1) pain, cervical range of motion (flexion: 8.41 & PLUSMN; 8.26 deg; extension: 12.23 & PLUSMN; 6.55; affected-side rotation: 14.27 & PLUSMN; 11.05; unaffected-side rotation: 11.73 & PLUSMN; 8.65; affected-side lateroflexion: 7.95 & PLUSMN; 5.1; unaffected-side lateroflexion: 9.55 & PLUSMN; 6.6), maximum mouth opening (3.36 & PLUSMN; 3.4 mm), and cervical muscle function (8.09 & PLUSMN; 6.96 s) in HNC survivors.